Changes in the clinical presentation and outcomes of patients treated for severe malaria in a referral French university intensive care unit from 2004 to 2017.
Artesunate
Critically ill
Outcome
Sepsis
Severe malaria
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
12 Feb 2020
12 Feb 2020
Historique:
received:
04
08
2019
accepted:
30
01
2020
entrez:
14
2
2020
pubmed:
14
2
2020
medline:
14
2
2020
Statut:
epublish
Résumé
In France, the incidence of severe imported malaria cases increased since early 2000. Artesunate was available (temporarily use authorization) since mid-2011 in France and commonly used for severe malaria since early 2013. Thus, the study objectives were to describe the patients with severe imported malaria admitted in intensive care unit (ICU) and assess the changes in clinical presentation and outcomes before and after this date. Retrospective observational single-center study in the infectious diseases ICU of a referral university hospital, conducted on patients admitted for severe imported malaria from 2004 to 2017. Demographic variables, severity scores, WHO's severity criteria on admission, treatment, and ICU and hospital lengths of stay were collected. Patients' characteristics and outcomes were compared between both periods. A poor outcome was defined as the composite endpoint of death, or requirement for vasopressors, invasive mechanical ventilation and/or renal replacement therapy. 189 patients were included, 98 in 2004-2012 and 91 in 2013-2017, most often from West and Central African countries (96%). The number of WHO criteria for severe malaria was comparable in both groups, but SAPS II, SOFA and ICU length of stay were significantly higher in 2004-2012, while patients of African origin living in France were less frequent (p < 0.01). The outcome was poor for 41/98 cases in 2004-2012 and 12/91 cases in 2013-2017 (p < 0.01). The risk factors of poor outcome on the multivariate logistic regression were a neurological failure (adjusted odds ratio (adjOR = 3.23; 95% CI (1.03-10.08), p = 0.004), cardio-circulatory failure (adjOR = 9.92; 95% CI (2.34-42), p = <0.01) and creatinine blood levels > 265 µmol/L (adjOR = 10.76; 95% CI (3.17-36.53), p < 0.01). In the multivariate analysis, IV artesunate was not associated with a better outcome. Patients of African origin did not seem to have a better outcome than Caucasian patients or those from other origins (adjOR = 0.59; 95% CI (0.21-1.65), p = 0.31). Patients with imported malaria admitted in ICU in 2013-2017 were less severely ill than those in 2004-2012. These trends could be partially explained by the increasing proportion of African patients visiting friends or relatives or living in endemic areas.
Sections du résumé
BACKGROUND
BACKGROUND
In France, the incidence of severe imported malaria cases increased since early 2000. Artesunate was available (temporarily use authorization) since mid-2011 in France and commonly used for severe malaria since early 2013. Thus, the study objectives were to describe the patients with severe imported malaria admitted in intensive care unit (ICU) and assess the changes in clinical presentation and outcomes before and after this date.
METHODS
METHODS
Retrospective observational single-center study in the infectious diseases ICU of a referral university hospital, conducted on patients admitted for severe imported malaria from 2004 to 2017. Demographic variables, severity scores, WHO's severity criteria on admission, treatment, and ICU and hospital lengths of stay were collected. Patients' characteristics and outcomes were compared between both periods. A poor outcome was defined as the composite endpoint of death, or requirement for vasopressors, invasive mechanical ventilation and/or renal replacement therapy.
RESULTS
RESULTS
189 patients were included, 98 in 2004-2012 and 91 in 2013-2017, most often from West and Central African countries (96%). The number of WHO criteria for severe malaria was comparable in both groups, but SAPS II, SOFA and ICU length of stay were significantly higher in 2004-2012, while patients of African origin living in France were less frequent (p < 0.01). The outcome was poor for 41/98 cases in 2004-2012 and 12/91 cases in 2013-2017 (p < 0.01). The risk factors of poor outcome on the multivariate logistic regression were a neurological failure (adjusted odds ratio (adjOR = 3.23; 95% CI (1.03-10.08), p = 0.004), cardio-circulatory failure (adjOR = 9.92; 95% CI (2.34-42), p = <0.01) and creatinine blood levels > 265 µmol/L (adjOR = 10.76; 95% CI (3.17-36.53), p < 0.01). In the multivariate analysis, IV artesunate was not associated with a better outcome. Patients of African origin did not seem to have a better outcome than Caucasian patients or those from other origins (adjOR = 0.59; 95% CI (0.21-1.65), p = 0.31).
CONCLUSION
CONCLUSIONS
Patients with imported malaria admitted in ICU in 2013-2017 were less severely ill than those in 2004-2012. These trends could be partially explained by the increasing proportion of African patients visiting friends or relatives or living in endemic areas.
Identifiants
pubmed: 32052207
doi: 10.1186/s13613-020-0634-4
pii: 10.1186/s13613-020-0634-4
pmc: PMC7016155
doi:
Types de publication
Journal Article
Langues
eng
Pagination
21Commentaires et corrections
Type : ErratumIn
Références
Travel Med Infect Dis. 2017 May - Jun;17:43-49
pubmed: 28554853
PLoS Med. 2012;9(8):e1001297
pubmed: 22927801
PLoS Genet. 2018 Jan 30;14(1):e1007172
pubmed: 29381699
N Engl J Med. 2014 Jul 31;371(5):482
pubmed: 25075849
Med Mal Infect. 2020 Mar;50(2):99-112
pubmed: 31257063
Lancet. 2013 Sep 7;382(9895):900-11
pubmed: 23594387
Lancet Haematol. 2018 Aug;5(8):e333-e345
pubmed: 30033078
Lancet Haematol. 2015 Oct;2(10):e437-44
pubmed: 26686045
PLoS Med. 2005 Aug;2(8):e204
pubmed: 16104831
Lancet. 2011 Oct 8;378(9799):1316-23
pubmed: 21903251
BMC Infect Dis. 2013 Mar 05;13:118
pubmed: 23497139
Clin Infect Dis. 2015 Nov 1;61(9):1441-4
pubmed: 26187021
Malar J. 2012 Mar 31;11:102
pubmed: 22462806
Malar J. 2014 Jun 16;13:236
pubmed: 24934404
Lancet. 2010 Nov 13;376(9753):1647-57
pubmed: 21062666
BMJ. 2012 Mar 27;344:e2116
pubmed: 22454091
Lancet Haematol. 2015 Apr;2(4):e140-9
pubmed: 26687956
Emerg Infect Dis. 2011 May;17(5):807-13
pubmed: 21529388
Intensive Care Med. 2016 Oct;42(10):1588-1596
pubmed: 27169586
Malar J. 2017 Jan 31;16(1):57
pubmed: 28143519
JAMA Netw Open. 2019 Apr 5;2(4):e191691
pubmed: 30951158
PLoS One. 2010 Oct 08;5(10):e13236
pubmed: 20949045
PLoS One. 2017 Jun 13;12(6):e0179146
pubmed: 28609450
Clin Infect Dis. 2020 Jan 2;70(2):280-287
pubmed: 30874798
PLoS One. 2017 Apr 14;12(4):e0175328
pubmed: 28410415
Pathog Glob Health. 2012 Jul;106(3):181-7
pubmed: 23265377
PLoS One. 2018 Sep 17;13(9):e0203229
pubmed: 30222732